SITE PROXIE FULL

Masimo has consistently outperformed for its long-term shareholders, driven by steady strategic and operational execution and disciplined capital allocation that has led to profitable, above-market growth.

Here are five important reasons why you should vote “FOR” Masimo’s director nominees―Julie Shimer, Ph.D., and H Michael Cohen―on the WHITE proxy card today: The Company’s mission, strategy and guiding principles are all at stake. Masimo is the market leader in non-invasive monitoring, with robust plans to continue leading and transforming healthcare and consumer health.Īt the upcoming Annual Meeting, you have a critical choice to make regarding your investment in the future of Masimo. Masimo is not an industry laggard that has nowhere to go but up. Koffey a foothold in the boardroom so he can try to scrap the approach that has served Masimo and its shareholders well for its entire history are immense. He has refused to even provide dates for Masimo’s Nominating Committee to interview Michelle Brennan, the other Politan nominee. He has sued the Company and its current and former Board members and has refused to collaborate with the Board to appoint two new directors independent of both Masimo and Politan for the benefit of all shareholders, insisting on a seat for himself despite clearly not meeting the Board’s criteria for new directors.

He lacks credibility and brings no industry experience, prior public company board service or diversity to Masimo. Even taking that dubious claim at face value, Mr. Koffey will deny they are seeking control and claim they only want greater oversight. Yet their comments on Masimo’s strategy and performance show a dangerous ignorance of how we have achieved our success, the returns on our investments in innovation, and the rationale for our strategy, as well as a reckless willingness to distort the truth in pursuit of their agenda. Koffey’s track record and his representatives’ statements in court all indicate that Politan is ultimately seeking control of Masimo’s future. Politan, a start-up activist hedge fund, and its founder and nominee Quentin Koffey, who has never even invested in, much less run, a medical technology company, want you to trust them to “fix” Masimo. And as we look to the future, we intend to grow Masimo by continuing to develop and commercialize breakthrough products for both the hospital and the home. Masimo has delivered exceptional shareholder returns from our initial public offering more than 15 years ago and over nearly all time periods. The entire Masimo team and Board of Directors remain deeply committed to this approach, which has created incredible value and earned Masimo a sterling reputation with its customers, investors, and even competitors. Masimo was founded in 1989 by our current Chairman and CEO, Joe Kiani, and has become one of the most successful medical technology companies in the world by adhering to its guiding principles and developing breakthrough innovations that improve lives.

SITE PROXIE FULL

To protect stockholders’ investment and to ensure Masimo continues to create value, the Board encourages stockholders to vote FOR Masimo’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D.įind our definitive proxy materials and more information on why your vote is so important to the future of Masimo at The full text of the Board’s letter to our stockholders can be found here: The letter outlines the management team and Board of Directors’ long track record of creating stockholder value, compelling strategy and responsive governance changes, in addition to detailing the risk Politan Capital Management (“Politan”) and its nominee Quentin Koffey pose to the Company’s strategy, principles and leadership.

IRVINE, Calif.-( BUSINESS WIRE)-The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders in connection with its definitive proxy materials filed on May 24, 2023, and the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.

Site proxie